TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16507846

Group type: EXPERIMENTAL
Intervention: Simple aspiration
Number of subjects: 137

Group type: COMPARATOR
Intervention: Tube thoracostomy
Number of subjects: 137
Study: 12045127

Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg plus isoniazid (INH)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg plus isoniazid (INH)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rifapentine 1,200 mg plus isoniazid (INH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control: Twice-weekly rifampin plus isoniazid (not explicitly detailed in the abstract)
Number of subjects: 150
Study: 9665011

Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (SN) with Phenihydine, n = 20
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral (SN) without Phenihydine, n = 12
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sandimmun (S)
Number of subjects: 42
Study: 7547114

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapeutic approaches
Number of subjects: 0
Study: 2220722

Group type: EXPERIMENTAL
Intervention: Brown‐McHardy (BMH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Microvasive Rigiflex (MVR)
Number of subjects: 20
Study: 601870

Group type: EXPERIMENTAL
Intervention: Chemotherapy with isoniazid and rifampicin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Chemotherapy with isoniazid and ethambutol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Surgical intervention (excision or aspiration)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Overall treatment progress
Number of subjects: 108
Study: 7215718

Group type: EXPERIMENTAL
Intervention: Carbenoxolone 150 mg/day for 6 months
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31585702

Group type: EXPERIMENTAL
Intervention: Smoking cessation medication prescription recommended by counselor
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Insurance status
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Use of inpatient smoking cessation medication
Number of subjects: 214
Study: 29985680

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (2 and 4 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole (long-term treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Number of subjects: 0
Study: 27087970

Group type: EXPERIMENTAL
Intervention: Acute MRI management
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 16
Study: 24516261

Group type: EXPERIMENTAL
Intervention: Alternate day therapy with atorvastatin 10 mg and fenofibrate 160 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Daily therapy with atorvastatin 10 mg and fenofibrate 160 mg
Number of subjects: 110
Study: 22545737

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for adherence and depression (CBT-AD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 89
Study: 21142446

Group type: EXPERIMENTAL
Intervention: HAART treatment interruption (TI)
Number of subjects: 0
Study: 17940308

Group type: EXPERIMENTAL
Intervention: 100-kVp protocol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 120-kVp protocol
Number of subjects: 60
Study: 15567883

Group type: EXPERIMENTAL
Intervention: Gentle mechanical pressure on the cervix using the vaginal speculum for 7 minutes after embryo transfer
Number of subjects: 639

Group type: COMPARATOR
Intervention: No pressure applied on the cervix during embryo transfer
Number of subjects: 639
Study: 12386638

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10188604

Group type: EXPERIMENTAL
Intervention: Dorsal interossei
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volar interossei
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumbrical muscles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrinsic muscles in neuroprosthesis
Number of subjects: 0
Study: 7581094

Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy at 0.3 microgram/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy at 1 microgram/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy at 3 micrograms/kg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhIL-6 therapy (all doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maximal tolerated dose of rhIL-6
Number of subjects: 20
Study: 2179979

Group type: EXPERIMENTAL
Intervention: High-dose piracetam (24 g per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose piracetam (6 g per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 380251

Group type: EXPERIMENTAL
Intervention: Naproxen sodium and naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29757433

Group type: EXPERIMENTAL
Intervention: Useful Field of View training (UFOVt)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cognitively stimulating activities (CSA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No-contact control (NC)
Number of subjects: 34
Study: 30650479

Group type: EXPERIMENTAL
Intervention: Shenmai Injection (SI), 50 mL each time, once per day for 10 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (conventional drugs for CHD)
Number of subjects: 100
Study: 26486191

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24755046

Group type: EXPERIMENTAL
Intervention: Single-point cane
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Standard walker (SW)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wheeled walker (WW)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Unassisted stair ascending and descending
Number of subjects: 14
Study: 21138718

Group type: EXPERIMENTAL
Intervention: Team Resilience training workshop (three 2-hour sessions over 3 consecutive days)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control stores (no intervention)
Number of subjects: 235
Study: 18556221

Group type: EXPERIMENTAL
Intervention: SF-SACRAH (short form score for the assessment and quantification of chronic rheumatic affections of the hands)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: SF-SACRAH
Number of subjects: 247
Study: 18074664

Group type: EXPERIMENTAL
Intervention: Esomeprazole magnesium 40 mg once daily for 2 to 12 months
Number of subjects: 146
Study: 15358033

Group type: EXPERIMENTAL
Intervention: NCX‐4016 800 mg twice a day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NCX‐4016 800 mg twice a day plus aspirin 325 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aspirin 325 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12502003

Group type: EXPERIMENTAL
Intervention: Multidirectional motion loci in THR patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal hip joint range of motion
Number of subjects: 0
Study: 10335027

Group type: EXPERIMENTAL
Intervention: spiramycin 3 MIU twice daily for 7 or 10 days
Number of subjects: 55

Group type: COMPARATOR
Intervention: clarithromycin 500 mg twice daily for 7 or 10 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: spiramycin
Number of subjects: 55

Group type: COMPARATOR
Intervention: clarithromycin
Number of subjects: 55
Study: 7666064

Group type: EXPERIMENTAL
Intervention: Lead II used most commonly with a single-channel system (66.3%)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Lead II plus V1 (or MCL1) selected most often with dual-channel systems (62.4%)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Modification of lead selection based on location of AMI reported by 20% of respondents
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Correct identification of classic ischemia, injury, and infarction by 43.3% of respondents
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Right precordial leads usage
Number of subjects: 882
Study: 2474848

Group type: EXPERIMENTAL
Intervention: 20 mM oleic acid
Number of subjects: 6

Group type: COMPARATOR
Intervention: 20 mM oleyl alcohol
Number of subjects: 6
Study: 412615

Group type: EXPERIMENTAL
Intervention: 4% disodium cromoglycate (DSCG) nasal solution
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29482026

Group type: EXPERIMENTAL
Intervention: High-dose diuretic strategy (median furosemide dose of 320 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose diuretic strategy (median furosemide dose of 840 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cystatin C (biomarker of renal dysfunction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose strategy in patients with eGFR below median
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced fluid output, weight loss, and diuretic efficiency (DE)
Number of subjects: 0
Study: 28352985

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg qd
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cabozantinib 100 mg qd and Erlotinib 50 mg qd
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cabozantinib 100 mg qd and Erlotinib 50 mg qd (phase I MTD)
Number of subjects: 64
Study: 26184340

Group type: EXPERIMENTAL
Intervention: Cereal labeled 'fruit sugar'
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cereal labeled 'sugar'
Number of subjects: 164
Study: 22956398

Group type: EXPERIMENTAL
Intervention: Single-port (SP) configuration
Number of subjects: 28

Group type: COMPARATOR
Intervention: 2-port (TP) configuration
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Training with TP followed by SP
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Training with SP followed by TP
Number of subjects: 28
Study: 20441725

Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy (3 to 5 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational sessions only (1 to 3 sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imaginal exposure therapy in subgroup with acute unscheduled cardiovascular events and high baseline PTSD symptoms
Number of subjects: 60
Study: 18602616

Group type: EXPERIMENTAL
Intervention: Trained group (healthy partner trained to direct intention toward the cancer patient)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Wait group (couples tested before the partner was trained)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (14 healthy couples received no training)
Number of subjects: 36
Study: 16387405

Group type: EXPERIMENTAL
Intervention: Gold bonder systems (two types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceramic Ti bonder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gold‐palladium PFM alloy
Number of subjects: 0
Study: 14649340

Group type: EXPERIMENTAL
Intervention: Non-blinded neuromuscular transmission monitoring with rocuronium infusion at 6 microg kg(‐1) min(‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blinded neuromuscular transmission monitoring with rocuronium infusion at 6 microg kg(‐1) min(‐1) (fixed rate)
Number of subjects: 20
Study: 11011985

Group type: EXPERIMENTAL
Intervention: Morning administration of OROS systems
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Night administration of OROS systems
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Comparison of OROS systems total transit time to intrinsic bowel movement pattern
Number of subjects: 1243
Study: 8661630

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 105
Study: 1505647

Group type: EXPERIMENTAL
Intervention: Nifedipine 80 mg/day
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 6650543

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31504329

Group type: EXPERIMENTAL
Intervention: Screening program for anal cancer prevention
Number of subjects: 3111

Group type: COMPARATOR
Intervention: Non-screening group
Number of subjects: 3111
Study: 29510461

Group type: EXPERIMENTAL
Intervention: Mexiletine 150 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27939406

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-modified allergen extracts administered via therapeutic vaccine adsorbed onto aluminium hydroxide
Number of subjects: 1855

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde-modified allergen extracts
Number of subjects: 1855
Study: 26146015

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quetiapine (25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Olanzapine and Quetiapine
Number of subjects: 6
Study: 23759449

Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Stress management training
Number of subjects: 111
Study: 21349452

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PEB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 50
Study: 19047719

Group type: EXPERIMENTAL
Intervention: Medial tibial slope in female subjects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lateral tibial slope in female subjects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Coronal tibial slope in female subjects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Within-subject differences between medial and lateral tibial slopes
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Medial tibial plateau depth
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Correlation between slopes and age
Number of subjects: 55
Study: 16572265

Group type: EXPERIMENTAL
Intervention: Ondansetron (12 mg, oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14598426

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 61

Group type: COMPARATOR
Intervention: Emergency Surgery
Number of subjects: 61
Study: 11908370

Group type: EXPERIMENTAL
Intervention: Colgate Actibrush (battery-powered toothbrush)
Number of subjects: 63

Group type: COMPARATOR
Intervention: ADA-provided manual toothbrush (control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Colgate Actibrush
Number of subjects: 63
Study: 8766415

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg t.i.d.)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril plus Aspirin (325 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalapril plus Aspirin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7893494

Group type: EXPERIMENTAL
Intervention: Warm retrograde blood cardioplegia (WRC) with Fremes solution (initially antegrade and retrograde high potassium solution, then continuous retrograde low potassium solution)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent oxygenated cold Fresenius solution antegrade and retrograde (FR)
Number of subjects: 60
Study: 3299089

Group type: EXPERIMENTAL
Intervention: 250 mg of AZT every four hours for 24 weeks
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 29317123

Group type: EXPERIMENTAL
Intervention: Baseline serum high‐sensitivity C‐reactive protein (hsCRP) values <10 mg/L categorized into tertiles
Number of subjects: 572
Study: 27716324

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 0
Study: 24720102

Group type: EXPERIMENTAL
Intervention: Outpatient cardiologic rehabilitation (24 forty-minute training sessions, 2-3 times a week for about 3 months)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no rehabilitation)
Number of subjects: 108
Study: 24388336

Group type: EXPERIMENTAL
Intervention: 16S rRNA PCR
Number of subjects: 706

Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 706
Study: 22731926

Group type: EXPERIMENTAL
Intervention: Internet intervention for amphetamine-type stimulant problems
Number of subjects: 160

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 160
Study: 20967275

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 993
Study: 18056488

Group type: EXPERIMENTAL
Intervention: Early passive mobilization (within three days after the fracture)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional treatment (three-week immobilization followed by physiotherapy)
Number of subjects: 74
Study: 16127964

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg daily (adjusted to a maximum of 20 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Haloperidol 2 mg daily (adjusted to a maximum of 20 mg daily)
Number of subjects: 18
Study: 12131428

Group type: EXPERIMENTAL
Intervention: Provocative discography screening (Group B)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No provocative discography screening (Group A)
Number of subjects: 73
Study: 10403589

Group type: EXPERIMENTAL
Intervention: Single booster vaccination (day 0)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Two booster vaccinations (day 0, 28)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 618
Study: 8968528

Group type: EXPERIMENTAL
Intervention: Deflazacort 3 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deflazacort 6 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deflazacort 36 mg
Number of subjects: 24
Study: 1424032

Group type: EXPERIMENTAL
Intervention: EPOCH 3,000 IU
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: EPOCH 6,000 IU
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: EPOCH 9,000 IU
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: EPOCH (any dose) with ABP
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control (no EPOCH, no ABP)
Number of subjects: 205
Study: 4051446

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Antrectomy
Number of subjects: 52
Study: 30690294

Group type: EXPERIMENTAL
Intervention: trametinib (2 mg orally, once daily; n = 214)
Number of subjects: 322

Group type: COMPARATOR
Intervention: chemotherapy (dacarbazine [1000 mg/m2] or paclitaxel [175 mg/m2] intravenously, every 3 weeks; n = 108)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: trametinib
Number of subjects: 322

Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 322
Study: 30527176

Group type: EXPERIMENTAL
Intervention: Early initiated postoperative rehabilitation (14 days after surgery)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Late initiated postoperative rehabilitation (14 weeks after surgery)
Number of subjects: 235
Study: 27433858

Group type: COMPARATOR
Intervention: Observation arm (no intervention)
Number of subjects: 80
Study: 25295436

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 40 minutes)
Number of subjects: 26
Study: 22852054

Group type: EXPERIMENTAL
Intervention: High-Fat Meal + Maltodextrin (HFM + M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Fat Meal + Placebo (HFM + P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-Carbohydrate Meal + Placebo (HCM + P)
Number of subjects: 0
Study: 20369312

Group type: EXPERIMENTAL
Intervention: Epoetin zeta
Number of subjects: 462

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 462
Study: 17646492

Group type: EXPERIMENTAL
Intervention: Dentures-In group (ventilated with dentures in place)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Dentures-Out group (ventilated with dentures removed)
Number of subjects: 166
Study: 16098604

Group type: EXPERIMENTAL
Intervention: rHuG-CSF (5 microg/kg daily for 3 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 12
Study: 12402720

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms kg‐1 infusion over 20 min, PCA clonidine 20 micrograms and morphine 1 mg bolus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion and PCA morphine 1 mg bolus
Number of subjects: 60
Study: 10363933

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over the visual cortex
Number of subjects: 0
Study: 8646021

Group type: EXPERIMENTAL
Intervention: Iron supplementation for three months
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo for three months
Number of subjects: 151
Study: 1384117

Group type: EXPERIMENTAL
Intervention: L-carnitine (5 g at hours 0, 12, 24, 36 and 2 x 3 g on days 3 to 7 by intravenous infusion over 2 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6535339

Group type: COMPARATOR
Intervention: Discontinue medication with no dietary intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinue medication and reduce weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinue medication and reduce sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continue medication
Number of subjects: 0
Study: 30665671

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20mL 0.5%)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Bupivacaine (20mL 0.5%) + Dexmedetomidine (1mL, 100μg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (Post-operative i.v. morphine via patient‐controlled analgesia without paravertebral blockade)
Number of subjects: 93
Study: 29571953

Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate (0.4 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control injection of sterile saline water
Number of subjects: 40
Study: 25911092

Group type: EXPERIMENTAL
Intervention: Standardized behavioral intervention
Number of subjects: 152
Study: 25060083

Group type: EXPERIMENTAL
Intervention: Bone scan within 3-5 days (n=12)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Traditional diagnosis (radiographs 10-14 days postinjury; n=15)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier survival analysis
Number of subjects: 27